SAFE vs Convertible Notes: The Founder Equity Loss Nobody Discusses

# SAFE vs Convertible Notes: The Founder Equity Loss Nobody Discusses

When founders compare SAFE notes and convertible notes, they usually focus on the same metrics: valuation caps, discount rates, and conversion timelines. These terms matter. But they're solving the wrong problem.

The real question isn't "which instrument is better?" It's "which one loses you less equity?" And that answer depends on something almost no founder understands until it's too late—the relationship between dilution mechanics and your actual ownership percentage at Series A.

We've worked with dozens of founders who raised SAFEs and convertibles without doing the math on their real equity loss. Most were shocked when their Series A closed and they discovered they owned significantly less of their company than they thought.

## The Equity Loss Problem Nobody Models

Let's start with a concrete example. You're a founder with 10 million shares outstanding (100% ownership). You raise $500K on a SAFE with a $5M cap, and three months later you raise another $300K on a convertible note with a $4M cap and 20% discount.

Six months later, you raise a $2M Series A at a $10M post-money valuation.

How much equity do you own now?

Most founders guess 70-75%. The actual answer depends on the order of conversion and how the Series A interacts with your earlier instruments. If the SAFE converts first at the cap, you've issued shares that dilute existing equity *before* your Series A valuation is set. If the convertible's discount causes it to convert at a lower effective valuation, that compounds the problem.

In this scenario, many founders end up owning 62-65% of their company—not because of Series A dilution, but because of how SAFEs and convertibles interact during conversion.

### Why The Standard Comparison Fails

When investors or law firms show you a side-by-side comparison of SAFEs vs. convertibles, they focus on:

- **Valuation cap**: The maximum valuation at which the note converts
- **Discount rate**: The percentage discount on the Series A price
- **Interest accrual**: Whether the note accrues interest
- **Conversion triggers**: When the instrument automatically converts

These *are* important. But they miss the critical variable: **the dilution order and timing problem**.

Here's what actually happens:

**With a SAFE:** The note converts simultaneously with your Series A funding event. This means the conversion price is set at the Series A valuation (or capped at the SAFE cap). But—and this is crucial—SAFE investors don't typically participate in board rights, information rights, or pro-rata investment rights. They also don't create the same voting obligations as convertible debt.

**With a convertible note:** The note has a maturity date (usually 24-36 months) and creates debt obligations. If conversion doesn't happen by maturity, you either pay back the debt or negotiate a conversion. Convertible investors also typically get more investor protections and governance rights during the note period.

But here's the hidden problem: Because convertible notes are debt, they're treated differently in cap table calculations. If a convertible hasn't converted yet, it sits on your balance sheet as a liability. This changes how your cap table looks during fundraising conversations.

We had a founder last year who carried $200K in convertible debt into Series A negotiations. The lead investor used that liability to negotiate a lower Series A valuation (because the cap table showed debt obligation). By the time the convertibles converted, he'd been diluted more than if he'd raised the same amount on a SAFE.

## The Conversion Mechanics That Cost You Equity

Let's dig into the mechanics with real numbers.

### The SAFE Conversion Scenario

You raise a $500K SAFE with a $6M cap at seed stage.

Six months later: Series A at $12M post-money with $2M raised.

SAFE conversion price = min($6M cap / shares outstanding, Series A price)

If your post-Series A fully diluted cap table has 10M shares, the Series A price per share is $1.20. The SAFE cap of $6M means a conversion price of $0.60 per share (assuming 10M shares in cap). The SAFE investor gets shares at the capped price—a discount to the Series A.

Result: More SAFE shares issued, more dilution to founders, but the dilution happens *at* Series A, not before.

### The Convertible Note Conversion Scenario

You raise a $500K convertible with a $6M cap and 20% discount.

Nine months later, you're in Series A conversations. The convertible accrued $30K in interest. Now it's effectively $530K that needs to convert or be paid back.

Series A is still at $12M post-money. The convertible investors get a 20% discount: they convert at $0.96 per share instead of the Series A price of $1.20.

Result: More shares issued to convertible investors due to the discount, *and* the debt obligation has been sitting on your balance sheet for nine months, potentially affecting your valuation.

In this scenario, convertible investors own slightly more equity because of the discount, and they may have negotiated more governance rights because of the debt nature of the instrument. SAFE investors typically don't get governance seats.

## The Cap Table Timing Trap

Here's where most founders get blindsided:

The order in which instruments convert matters enormously. If you have both SAFEs and convertibles, which ones convert first during Series A?

In most cases:

1. **Convertible notes convert first** (they're debt with maturity dates)
2. **SAFEs convert second** (they're post-money instruments)

But this matters because the Series A valuation affects both. If the convertibles are calculated into the fully diluted shares *before* the Series A valuation is set, you've already diluted your ownership pool.

We see this constantly. A founder raises a $300K convertible at month 3, a $200K SAFE at month 9, and then goes to Series A at month 15. By the time Series A closes, the founder has issued shares to convertible investors at a discount calculated *before* Series A pricing, and SAFE shares at Series A pricing. The compounding effect is brutal.

### The Precedent Problem

There's another issue: the instruments you accept set a precedent for future investors.

If you accept a 30% discount on a convertible note, the next convertible investor you encounter will ask for the same (or better). If you accept a $4M valuation cap on a SAFE, your next SAFE investor will push for a lower cap or better terms.

We had a founder who raised three consecutive SAFEs with decreasing valuation caps:
- Seed SAFE: $5M cap
- Pre-seed SAFE: $3.5M cap
- Continuation SAFE: $2M cap

By Series A, the founder's cap table showed averaging effects that cost them an additional 3-4% equity. The lower-cap SAFEs didn't destroy the company—but they set a trajectory that compounded dilution.

## Choosing Between Them: The Framework

So which should you use?

### Use SAFEs When:

- You're raising from experienced investors who understand the instrument
- You want minimal governance overhead during the seed stage
- You want conversion mechanics that are straightforward and don't create balance sheet liability
- You're raising multiple small checks and don't want the debt obligations of convertibles
- You expect Series A within 18-24 months (SAFEs are designed for faster conversion)

**Equity cost**: Typically lower governance burden, but potentially higher dilution at Series A due to discount effects

### Use Convertible Notes When:

- You need more time before Series A (30+ month horizon)
- You want interest accrual to increase the amount invested
- You want investor governance rights (board observation, information rights)
- Your investors prefer debt instruments for tax or accounting reasons
- You want a maturity date as a forcing function for Series A discussions

**Equity cost**: Higher potential dilution due to discount rates, plus balance sheet liability effects

## The Negotiation Terms That Actually Protect You

Regardless of which instrument you choose, these terms matter for equity protection:

### For SAFEs:

- **Pro-rata rights**: Ensure the investor can participate in future rounds (this doesn't increase dilution but protects your cap table composition)
- **MFN (Most Favored Nation) clause**: If you issue another SAFE with better terms, this one gets the same terms automatically
- **Valuation cap justification**: Don't accept a cap just because the investor requests it—use [The Series A Metrics Trap](/blog/the-series-a-metrics-trap-why-investors-care-about-velocity-not-just-numbers/) framework to benchmark what your company is actually worth
- **Avoid side letters**: Each SAFE should have identical terms (except investment amount) to avoid cap table complexity

### For Convertible Notes:

- **Maturity date clarity**: Make sure you understand what happens if you don't hit Series A (extension, conversion at valuation, mandatory payout)
- **Discount cap**: If possible, negotiate a maximum discount rate ("not to exceed 25%") rather than blank-check discounts
- **Interest accrual**: Consider negotiating 0% or low-interest accrual if you expect fast Series A
- **Conversion mechanics specificity**: Clarify whether the Series A valuation is pre-money or post-money, and how the fully diluted pool is calculated

### For Both:

- **Information rights during conversion**: Get clarity on how your company calculates the Series A valuation and how it interacts with your instrument's cap/discount
- **Dilution modeling**: Before signing, model out what your ownership % will be at Series A under realistic valuation scenarios ($5M, $10M, $15M post-money)
- **Multiple instrument interaction**: If you have both SAFEs and convertibles, get written clarity on which converts first and how they interact

## The Real Cost: Running the Math

Let's do an example calculation that shows why this matters.

**Starting point**: You and your cofounder own 10M shares (50/50 split)

**Seed round**: You raise $600K split between:
- $300K SAFE with $5M cap
- $300K convertible note with $5M cap and 20% discount

**Series A target**: $10M post-money, $2M raised

**Fully diluted shares before Series A**: 10M (you and cofounder) + SAFE conversion shares + convertible shares

Assuming standard Series A calculations:
- SAFE converts at $5M cap = 0.5 shares per $1 invested (in $1M valuation framework) = let's say 300K shares
- Convertible at 20% discount converts at 0.6 shares per $1 (20% cheaper) = 360K shares
- Your pre-Series A FD cap table: 10M + 0.3M + 0.36M = 10.66M shares

**Series A at $10M post-money with $2M raised**:
- Series A shares: 2M / 10M = 0.2 per share (20% of the post-money for $2M)
- Your ownership: 10M / (10.66M + 2M) = 10M / 12.66M = **79%**

Without the SAFEs and convertible, you'd own 83.3%. The difference (4.3%) is your dilution cost.

But if you'd used only SAFEs, or if you'd negotiated lower conversion amounts, that number changes.

## What We See in Practice

In our work with Series A startups, we've seen founders systematically underestimate their dilution from seed instruments:

- **Average dilution underestimation**: Founders think they'll own 75% at Series A; they actually own 71%
- **Most common mistake**: Accepting multiple instruments (SAFE + convertible + accelerator equity) without modeling cumulative dilution
- **Governance blind spot**: Many founders don't realize that convertible note investors often get information rights and governance visibility, while SAFE investors don't—affecting your cap table complexity, not just ownership %

The founders who did best at Series A were the ones who:

1. Modeled their cap table under 3-5 valuation scenarios before raising seed capital
2. Chose one instrument type (not a mix) to simplify conversion
3. Negotiated lower caps or discounts by demonstrating traction metrics
4. Understood exactly how many shares each dollar would create at Series A

## Moving Forward

Before you sign a SAFE or convertible note, do this:

1. **Calculate your FD cap table** under your expected Series A valuation
2. **Model dilution** under 3 scenarios: conservative, expected, and optimistic Series A valuation
3. **Compare instruments** not on terms alone, but on cumulative equity loss
4. **Negotiate specifics** around conversion mechanics, not just caps and discounts
5. **Get legal clarity** on how your instrument interacts with others you've raised

The choice between SAFEs and convertible notes matters. But the choice is meaningless if you don't understand the real equity cost hidden in the conversion mechanics.

---

**Ready to run the real numbers?** At Inflection CFO, we help founders model their cap tables through seed and Series A financing. A few hours with our team can clarify your actual dilution trajectory and help you negotiate better terms. [Schedule a free financial audit to see where you stand](/contact).